•
Sep 30, 2024

Surgery Partners Q3 2024 Earnings Report

Reported strong growth in Adjusted EBITDA and revenue, driven by core organic growth and inorganic growth strategies.

Key Takeaways

Surgery Partners reported a 14.3% increase in revenue to $770.4 million for the third quarter of 2024. Adjusted EBITDA was $128.6 million, representing a 21.9% increase compared to the prior year period. The company reaffirmed its full-year 2024 revenue and Adjusted EBITDA guidance.

Revenues increased by 14.3% to $770.4 million compared to the prior year period.

Same-facility revenues increased by 4.2%.

Adjusted EBITDA was $128.6 million, a 21.9% increase year-over-year.

Adjusted EBITDA margin expanded by 100 basis points to 16.7%.

Total Revenue
$770M
Previous year: $674M
+14.3%
EPS
$0.19
Previous year: $0.19
+0.0%
Days adjusted revenue growth
4.2%
Previous year: 14.2%
-70.4%
Cases
176.65K
Previous year: 146.51K
+20.6%
Revenue per case
$4.72K
Previous year: $4.6K
+2.5%
Gross Profit
$127M
Previous year: $137M
-7.0%
Cash and Equivalents
$222M
Previous year: $236M
-6.0%
Free Cash Flow
$45M
Previous year: $63.2M
-28.8%
Total Assets
$7.53B
Previous year: $6.78B
+11.1%

Surgery Partners

Surgery Partners

Surgery Partners Revenue by Segment

Forward Guidance

The Company reaffirmed its outlook for 2024 revenues and Adjusted EBITDA to be greater than $3.075 billion and greater than $508 million, respectively.

Revenue & Expenses

Visualization of income flow from segment revenue to net income